Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. (9th February 2023)

• Record Type: Journal Article
• Authors: Mwimanzi, Francis; Lapointe, Hope R; Cheung, Peter K; Sang, Yurou; Yaseen, Fatima; Kalikawe, Rebecca; Datwani, Sneha; Burns, Laura; Young, Landon; Leung, Victor; Ennis, Siobhan; Brumme, Chanson J; Montaner, Julio S G; Dong, Winnie; Prystajecky, Natalie; Lowe, Christopher F; DeMarco, Mari L; Holmes, Daniel T; Simons, Janet; Niikura, Masahiro; Romney, Marc G; Brumme, Zabrina L; Brockman, Mark A
• Is Part Of: Open forum infectious diseases. Volume 10:Number 3(2023)
• Publication Date: 2023-02-09
• Subjects: COVID-19 -- mRNA vaccine -- older adults -- Omicron -- postvaccination infection; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofad073
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. Methods: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24–98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time. Results: Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk. Conclusions: Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses. Abstract : After 3 COVID-19 mRNA vaccine doses, younger and older adults show similar WT and Omicron-BA.1-specific antibody magnitude and durability, but BA.1-specific neutralization declines faster in older adults. SARS-CoV-2 breakthrough infection enhances responses, but Omicron-BA.5 neutralization remains poorer than against BA.1.